BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Company update

MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

LXRXLexicon Pharmaceuticals2026-09-01 20:05 EST

Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

RYTMRhythm Pharmaceuticals2026-08-04 20:01 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

MNKDMannKind2026-09-02 12:30 EST

MannKind to Present at Upcoming Investor Conferences

SENSSenseonics2026-09-10 12:00 EST

Senseonics To Participate in Upcoming Institutional Investor Conferences

VANIVivani Medical2026-09-03 20:08 EST

Vivani Medical Announces Participation in Upcoming Investor Conferences

VKTXViking Therapeutics2026-09-02 20:05 EST

Viking Therapeutics to Participate at Upcoming Investor Conferences

NAMSNewAmsterdam Pharma2026-09-02 12:00 EST

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September

SGMTSagimet Biosciences2026-09-02 11:00 EST

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-09-03 13:35 EST

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

MISTMilestone Pharmaceuticals Inc.2026-09-02 12:00 EST

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MISTMilestone Pharmaceuticals Inc.2026-08-27 12:00 EST

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Stock data

Close
0.92 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States